4
MARKET OVERVIEW
Summarizes the competitive environment, macro signals, and segment-level movements driving market outcomes.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
5.1
PORTER'S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC INDICATORS
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL MOLECULAR DIAGNOSTICS INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTICS PRODUCTS, BY PRODUCT, 2024-2026
5.6.2
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024-2026
5.6.3
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTICS PRODUCTS, BY REGION, 2024-2026
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.12
IMPACT OF 2025 US TARIFF – MOLECULAR DIAGNOSTICS MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES/REGIONS
5.12.5
IMPACT ON END USERS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.6
IMPACT OF AI/GEN AI ON MOLECULAR DIAGNOSTICS MARKET
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
BEST PRACTICES IN MOLECULAR DIAGNOSTICS MARKET
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN MOLECULAR DIAGNOSTICS MARKET
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS' READINESS TO ADOPT GENERATIVE AI IN MOLECULAR DIAGNOSTICS MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MOLECULAR DIAGNOSTICS MARKET
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END USERS
9
MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
10
MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
11
MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
11.2
BLOOD, SERUM, AND PLASMA
12
MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
12.2
POLYMERASE CHAIN REACTION
12.2.3
SERVICES & SOFTWARE
12.3
ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
12.2.3
SERVICES & SOFTWARE
12.4
DNA SEQUENCING & NEXT-GENERATION SEQUENCING
12.2.3
SERVICES & SOFTWARE
12.5
IN SITU HYBRIDIZATION
12.2.3
SERVICES & SOFTWARE
12.2.3
SERVICES & SOFTWARE
13
MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
13.2
INFECTIOUS DISEASE DIAGNOSTICS
13.2.1
SEXUALLY TRANSMITTED DISEASES
13.2.1.5
OTHER SEXUALLY TRANSMITTED DISEASES
13.2.2.3
OTHER HEPATITIS DISEASES
13.2.3
RESPIRATORY INFECTIOUS DISEASES
13.2.3.4
OTHER RESPIRATORY INFECTIOUS DISEASES
13.2.4
HOSPITAL-ACQUIRED INFECTIONS
13.2.5
VECTOR-BORNE DISEASES
13.2.6
OTHER INFECTIOUS DISEASES
13.3.5
OTHER CANCER TYPES
14
MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
15
MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
16
MOLECULAR DIAGNOSTICS MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
16.2
DIAGNOSTIC LABORATORIES
17
MOLECULAR DIAGNOSTICS MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
17.4.6
REST OF ASIA PACIFIC
17.5.3
REST OF LATIN AMERICA
17.6
MIDDLE EAST & AFRICA
17.6.3
REST OF MIDDLE EAST & AFRICA
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
18.4
MARKET SHARE ANALYSIS
18.4.1
GLOBAL MARKET SHARE ANALYSIS
18.4.2
US MARKET SHARE ANALYSIS
18.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
18.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
18.6.5.1
COMPANY FOOTPRINT
18.6.5.2
REGION FOOTPRINT
18.6.5.3
PRODUCT & SERVICE FOOTPRINT
18.6.5.4
TEST TYPE FOOTPRINT
18.6.5.5
SAMPLE TYPE FOOTPRINT
18.6.5.6
TECHNOLOGY FOOTPRINT
18.6.5.7
APPLICATION FOOTPRINT
18.6.5.8
TECHNIQUE FOOTPRINT
18.6.5.9
CLINICAL APPLICATION FOOTPRINT
18.6.5.10
END USER FOOTPRINT
18.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
18.7.1
PROGRESSIVE COMPANIES
18.7.2
RESPONSIVE COMPANIES
18.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
18.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
18.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
18.8
COMPANY VALUATION AND FINANCIAL METRICS
18.9
COMPETITIVE SCENARIO
19.1.1
DANAHER CORPORATION
19.1.2
F. HOFFMANN-LA ROCHE LTD
19.1.7
THERMO FISHER SCIENTIFIC INC.
19.1.8
ABBOTT LABORATORIES
19.1.9
SIEMENS HEALTHINEERS AG
19.1.10
BD DIAGNOSTIC SOLUTIONS (NOW WATERS ADVANCED DIAGNOSTICS)
19.1.11
AGILENT TECHNOLOGIES
19.1.15
SANSURE BIOTECH INC.
19.2.1
QUIDELORTHO CORPORATION
19.2.2
GENETIC SIGNATURES LTD.
19.2.5
MEDIGEN BIOTECHNOLOGY CORP.
19.2.7
AMOY DIAGNOSTICS CO., LTD.
19.2.8
BRUKER CORPORATION
19.2.9
MOLBIO DIAGNOSTICS LIMITED
19.2.10
GENEOBIOMIO TECHNOLOGIES PVT. LTD.
19.2.11
SAVYON DIAGNOSTICS LTD.
19.2.13
SYSMEX CORPORATION
19.2.14
BIO RAD LABORATORIES
19.2.15
SD BIOSENSORS, INC.
20.1.1.1
KEY DATA FROM SECONDARY SOURCES
20.1.2.1
KEY DATA FROM PRIMARY SOURCES
20.1.2.2
KEY PRIMARY PARTICIPANTS
20.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
20.1.2.4
KEY INDUSTRY INSIGHTS
20.2
MARKET SIZE ESTIMATION
20.2.1
BOTTOM-UP APPROACH
20.2.3
BASE NUMBER CALCULATION
20.3
MARKET FORECAST APPROACH
20.6
RESEARCH ASSUMPTIONS
20.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
21.3
CUSTOMIZATION OPTIONS
MnM
Jun, 2022
• Due to covid, there was an increase in the demand for immunodiagnostics and molecular testing, which was regarded as the gold standard for diagnosing infectious diseases, leading to the increased sales of related consumables and kits. During the pandemic era, revenue growth for key players was majorly driven by the sales of COVID-19 diagnostic tests. The dominant model of laboratory testing throughout the world remains the centralized laboratory that uses automated analytical testing methods to detect target analytes. This trend is well established in clinical chemistry and haematology disciplines and is now extending to other areas, including immunoassays and molecular diagnostics. Reagents & kits segment accounted for the largest share in the IVD market and Oncology segment is expected to witness the fastest growth in the forecast period. With 30,000+ partners, technologies, and use-cases as the primary levers, we have deep understanding of IVD ecosystem. We offer more than 2X coverage throughout the IVD curve as compared to our competitors..
MnM
Jun, 2022
•The molecular diagnostics market is segmented into lab tests and PoC tests by test type. The lab tests segment accounted for the largest share of the molecular diagnostics market in 2021. Factors such as the increasing need for automation and the rising incidence of various infectious diseases are driving the growth of this segment. •Molecular diagnostic reagents include disease-specific kits and general reagents used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more accurate identification of specific pathogen strains in a patient sample. General reagents are key components of a majority of conventional molecular diagnostic procedures. • Companies are now launching rapid kits and reagents to detect the novel coronavirus, which is further fueling the growth of this market segment. Regional authorities have also been actively engaged in providing emergency approvals for the use of these kits. In September 2020, Danaher Corporation (US) received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. In March 2020, QIAGEN N.V. (Netherlands) received FDA approval for its QIAstat-Dx test kit to detect coronavirus. .
Maverick
Jun, 2026
I went through the Molecular Diagnostics Market report to assess growth drivers, and it helped me better understand how infectious disease testing and oncology applications are shaping revenue opportunities across regions..
Briar
Jun, 2026
Reviewing the Molecular Diagnostics Market insights gave me a clearer technical perspective on how PCR and next-generation sequencing platforms are evolving and influencing lab adoption strategies..
Delaney
Jun, 2026
From an investment standpoint, the Molecular Diagnostics Market analysis provided useful clarity on competitive positioning and where mid-sized players can realistically capture share in a rapidly consolidating space..